[an error occurred while processing this directive] | [an error occurred while processing this directive]
Research progress on application of radiotherapy to sensitize PD-1/PD-L1 inhibitors
Kong Yuehong, Ma Yifu, Zhao Xiangrong, Zhang Liyuan
Department of Radiotherapy & Oncology, the Second Affiliated Hospital of Soochow University,Laboratory of Cancer Radioimmunotherapy, the Second Affiliated Hospital of Soochow University,Suzhou Key Laboratory for Combined Radiotherapy and Immunotherapy of Cancer, Suzhou 215104, China
Abstract Programmed cell death-1/programmed cell death-ligand 1(PD-1/PD-L1) inhibitors have been approved for a variety of tumors, whereas the efficacy as monotherapy is low. How to sensitize the efficacy of PD-1/PD-L1 inhibitors through combined radiotherapy is the current research focus. Multiple studies have demonstrated that the combination of radiotherapy and anti-PD-1/PD-L1 therapy has yielded survival benefits. Nevertheless, ionizing radiation is a double-edged sword for anti-PD-1/PD-L1 therapy. For patients with metastatic cancers, radiotherapy should be fully exerted as a sensitizer to systemic anti-PD-1/PD-L1 therapy and the immunosuppressive effects should be avoided as much as possible. It is closely correlated with the selection of radiation dose, fraction size, treatment timing and irradiated numbers and sites. Therefore, this article reviews how to optimize radiotherapy combined with anti-PD-1/PD-L1 treatment scheduled for advanced stage metastatic cancers.
Fund:Suzhou Key Laboratory of Tumor Radiotherapy (szs2020309);Provincial Key Laboratory of Soochow University (KJS1961);Suzhou Science and Technology Development Plan (Basic Research on Minsheng Science and Technology-Health Application)(SYS2020143);Suzhou Clinical Key Disease Diagnosis and Treatment Technology Project (LCZX201808)
Kong Yuehong,Ma Yifu,Zhao Xiangrong et al. Research progress on application of radiotherapy to sensitize PD-1/PD-L1 inhibitors[J]. Chinese Journal of Radiation Oncology, 2021, 30(9): 984-988.
Kong Yuehong,Ma Yifu,Zhao Xiangrong et al. Research progress on application of radiotherapy to sensitize PD-1/PD-L1 inhibitors[J]. Chinese Journal of Radiation Oncology, 2021, 30(9): 984-988.
[1] Miller KD, Nogueira L, Mariotto AB, et al.Cancer treatment and survivorship statistics, 2019[J]. CA Cancer J Clin, 2019, 69(5):363-385.DOI:10.3322/caac.21565. [2] Ribas A, Wolchok JD.Cancer immunotherapy using checkpoint blockade[J]. Science, 2018, 359(6382):1350-1355.DOI:10.1126/science.aar4060. [3] Yamamoto K, Venida A, Yano J, et al.Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I[J]. Nature, 2020, 581(7806):100-105.DOI:10.1038/s41586-020-2229-5. [4] Bernstein MB, Krishnan S, Hodge JW, et al.Immunotherapy and stereotactic ablative radiotherapy (ISABR):a curative approach?[J]. Nat Rev Clin Oncol, 2016, 13(8):516-24.DOI:10.1038/nrclinonc.2016.30. [5] Sato H, Niimi A, Yasuhara T, et al.DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells[J]. Nat Commun, 2017, 8(1):1751.DOI:10.1038/s41467-017-01883-9. [6] Menon H, Ramapriyan R, Cushman TR, et al.Role of radiation therapy in modulation of the tumor stroma and microenvironment[J]. Front Immunol, 2019, 10:193.DOI:10.3389/fimmu.2019.00193. [7] Brooks ED, Chang JY.Time to abandon single-site irradiation for inducing abscopal effects[J]. Nat Rev Clin Oncol, 2019, 16(2):123-135.DOI:10.1038/s41571-018-0119-7. [8] Kulzer L, Rubner Y, Deloch L, et al.Norm-and hypo-fractionated radiotherapy is capable of activating human dendritic cells[J]. J Immunotoxicol, 2014, 11(4):328-336.DOI:10.3109/1547691x.2014.880533. [9] Lan J, Li R, Yin LM, et al.Targeting myeloid-derived suppressor cells and programmed death ligand 1 confers therapeutic advantage of ablative hypofractionated radiation therapy compared with conventional fractionated radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2018, 101(1):74-87.DOI:10.1016/j.ijrobp.2018.01.071. [10] Pike L RG, Bang A, Mahal BA, et al.The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors[J]. Int J Radiat Oncol Biol Phys, 2019, 103(1):142-151.DOI:10.1016/j.ijrobp.2018.09.010. [11] Vanpouille-Box C, Pilones KA, Wennerberg E, et al.In situ vaccination by radiotherapy to improve responses to antiCTLA-4 treatment[J]. Vaccine, 2015, 33(51):7415-7422.DOI:10.1016/j.vaccine.2015.05.105. [12] Formenti SC, Demaria S.Radiation therapy to convert the tumor into an in situ vaccine[J]. Int J Radiat Oncol Biol Phys, 2012, 84(4):879-880.DOI:10.1016/j.ijrobp.2012.06.020. [13] Schaue D, Ratikan JA, Iwamoto KS, et al.Maximizing tumor immunity with fractionated radiation[J]. Int J Radiat Oncol Biol Phys, 2012, 83(4):1306-1310.DOI:10.1016/j.ijrobp.2011.09.049. [14] Vanpouille-Box C, Alard A, Aryankalayil MJ, et al.DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity[J]. Nat Commun, 2017, 8(8):15618.DOI:10.1038/ncomms15618. [15] Luke JJ, Lemons JM, Karrison TG, et al.Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors[J]. J Clin Oncol, 2018, 36(16):1611-1618.DOI:10.1200/JCO.2017.76.2229. [16] Theelen W, Peulen HMU, Lalezari F, et al.Effect of pembrolizumab after stereotactic body radiotherapy vs. pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer:results of the PEMBRO-RT Phase 2 randomized clinical trial[J]. JAMA Oncol, 2019, 5(9):1276-1282.DOI:10.1001/jamaoncol.2019.1478. [17] Guckenberger M, Lievens Y, Bouma AB, et al.Characterisation and classification of oligometastatic disease:a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation[J]. Lancet Oncol, 2020, 21(1):e18-e28.DOI:10.1016/s1470-2045(19)30718-1. [18] Palma DA, Olson R, Harrow S, et al.Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers:long-term results of the SABR-COMET Phase Ⅱ randomized trial[J]. J Clin Oncol, 2020, 38(25):2830-2838.DOI:10.1200/JCO.20.00818. [19] Palma DA, Olson R, Harrow S, et al.Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET):a randomised, phase 2, open-label trial[J]. Lancet, 2019, 393(10185):2051-2058.DOI:10.1016/s0140-6736(18)32487-5. [20] Welsh J, Menon H, Chen D, et al.Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer:a randomized phase Ⅰ/Ⅱ trial[J]. J Immunother Cancer, 2020, 8(2):e001001.DOI:10.1136/jitc-2020-001001. [21] Theelen W, Chen D, Verma V, et al.Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer:a pooled analysis of two randomised trials[J]. Lancet Respir Med, 2021, 9(5):467-475.DOI:10.1016/S2213-2600(20)30391-X. [22] Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al.Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade[J]. Cancer Res, 2014, 74(19):5458-5468.DOI:10.1158/0008-5472.CAN-14-1258. [23] Deng L, Liang H, Burnette B, et al.Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J]. J Clin Invest, 2014, 124(2):687-695.DOI:10.1172/JCI67313. [24] Rodriguez-Ruiz ME, Rodriguez I, Garasa S, et al.Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mabs and are dependent on cd8 t cells and crosspriming[J]. Cancer Res, 2016, 76(20):5994-6005.DOI:10.1158/0008-5472.CAN-16-0549. [25] Sharabi AB, Nirschl CJ, Kochel CM, et al.Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen[J]. Cancer Immunol Res, 2015, 3(4):345-355.DOI:10.1158/2326-6066.CIR-14-0196. [26] Park SS, Dong H, Liu X, et al.PD-1 restrains radiotherapy-induced abscopal effect[J]. Cancer Immunol Res, 2015, 3(6):610-619.DOI:10.1158/2326-6066.CIR-14-0138. [27] Herter-Sprie GS, Koyama S, Korideck H, et al.Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer[J]. JCI Insight, 2016, 1(9):e87415.DOI:10.1172/jci.insight.87415. [28] Antonia SJ, Villegas A, Daniel D, et al.Overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC[J]. N Engl J Med, 2018, 379(24):2342-2350.DOI:10.1056/NEJMoa1809697. [29] Goto T.Radiation as an in situ auto-vaccination:current perspectives and challenges[J]. Vaccines (Basel) 2019, 7(3):100.DOI:10.3390/vaccines7030100. [30] Sundahl N, Vandekerkhove G, Decaestecker K, et al.Randomized Phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma[J]. Eur Urol, 2019, 75(5):707-711.DOI:10.1016/j.eururo.2019.01.009. [31] Zhang N, Zhu X, Kong C, et al.Application of anti-PD1 drugs before or during thoracic radiotherapy increases the incidence of radiation pneumonia compared to the application after radiotherapy[J]. Ann Oncol, 2020, 31:S1081.DOI:10.1016/j.annonc.2020.08.1450. [32] Teng F, Li M, Yu J.Radiation recall pneumonitis induced by PD-1/PD-L1 blockades:mechanisms and therapeutic implications[J]. BMC Med, 2020, 18(1):275.DOI:10.1186/s12916-020-01718-3. [33] Huang AC, Postow MA, Orlowski RJ, et al.T-cell invigoration to tumour burden ratio associated with anti-PD-1 response[J]. Nature, 2017, 545(7652):60-65.DOI:10.1038/nature22079. [34] Golden EB, Marciscano AE, Formenti SC.Radiation therapy and the in situ vaccination approach[J]. Int J Radiat Oncol Biol Phys, 2020, 108(4):891-898.DOI:10.1016/j.ijrobp.2020.08.023. [35] Bauml JM, Mick R, Ciunci C, et al.Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer:a phase 2 trial[J]. JAMA Oncol, 2019, 5(9):1283-1290.DOI:10.1001/jamaoncol.2019.1449. [36] Tubin S, Popper HH, Brcic L.Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY):improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects[J]. Radiat Oncol, 2019, 14(1):21.DOI:10.1186/s13014-019-1227-y. [37] Yin L, Xue J, Li R, et al.Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2020, 108(1):212-224.DOI:10.1016/j.ijrobp.2020.05.002. [38] Barsoumian HB, Ramapriyan R, Younes AI, et al.Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma[J]. J Immunother Cancer, 2020, 8:e000537.DOI:10.1136/jitc-2020-000537. [39] Jing H, Hettich M, Gaedicke S, et al.Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation[J]. J Immunother Cancer, 2019, 7(1):55.DOI:10.1186/s40425-019-0537-9. [40] Seung SK, Curti BD, Crittenden M, et al.Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and immunological responses[J]. Sci Transl Med, 2012, 4(137):137ra74.DOI:10.1126/scitranslmed.3003649. [41] Gurbatri CR, Lia I, Vincent R, et al.Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies[J]. Sci Transl Med, 2020, 12(530):eaax0876.DOI:10.1126/scitranslmed.aax0876. [42] Doi T, Piha-Paul SA, Jalal SI, et al.Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma[J]. J Clin Oncol, 2018, 36(1):61-67.DOI:10.1200/JCO.2017.74.9846. [43] Golden EB, Chhabra A, Chachoua A, et al.Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours:a proof-of-principle trial[J]. Lancet Oncol, 2015, 16(7):795-803.DOI:10.1016/S1470-2045(15)00054-6. [44] Kong Y, Zhao X, Li Z, et al.PD-1 inhibitor combined with radiotherapy and GM-CSF as salvage therapy in patients with chemotherapy-refractory metastatic solid tumors[J]. J Clinl Oncol, 2020, 38(15 suppl):e15173.DOI:10.1200/JCO.2020.38.15_suppl.e15173.
2021, Vol. 30 
